Platelet function tests using platelet aggregometry: need for repetition of the test for diagnosis of defective platelet function.
Four hundred and ninety seven patients were referred to our center for platelet aggregation studies because of spontaneous mucocutaneous bleeds. All these patients had normal complete blood count, platelet count and peripheral smears except in ten patients of Bernard Soulier Syndrome where platelet count was marginally reduced in the presence of giant platelets. Two hundred and eighty patients were found to have normal platelet aggregation to ADP, collagen, ristocetin and arachidonic acid. Out of the remaining 217 patients, 62 patients were diagnosed to have Glanzmanns thrombasthenia, 10 Bernard Soulier Syndrome, 6 storage pool deficiencies, 7 cyclooxygenase deficiencies and 72 von Willebrand disease. In all the patients with GT and BSS, diagnosis was confirmed with flow cytometry using multiple monoclonal antibodies to GPIIb-IIIa and GPIb-IX. There were sixty patients where initial platelet aggregation studies showed reduced (<30%) aggregation to either ADP, collagen, ristocetin or arachidonic acid in its various combination, however in 12 such patients (20%) the platelet aggregation studies were normal on repetition. All our platelet aggregation studies were done only after assuring that the patient is not taking any medicine for at least 7-10 days which may affect the platelet function tests. The present study shows that single atypically abnormal platelet aggregation studies should always be repeated. Finally in 48/217 patients (22%) some aggregation abnormality to one or more of the agonists persisted, although we could not categorize these patients into any clear-cut platelet disorder. None of these 48 patients platelet associated immunoglobulin was increased by flow cytometry. It is possible that large number of patients from that disorder will finally prove to be some form of platelet secretory defect. In north India similar group of defect in a large number of patients have been reported as isolated PF3 abnormality or thrombasthenic thrombopathy.
Ghosh
K
K
Institute of Immunohaematology, (ICMR), KEM Hospital, Parel, Mumbai, India.
Nair
S
S
Kulkarni
B
B
Khare
A
A
Shetty
S
S
Mohanty
D
D
D000244:Adenosine Diphosphate / Q000494:pharmacology; D016718:Arachidonic Acid / Q000494:pharmacology; D001606:Bernard-Soulier Syndrome / Q000097:blood / Q000175:diagnosis; D001778:Blood Coagulation Disorders / Q000097:blood / Q000175:diagnosis*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D003094:Collagen / Q000494:pharmacology; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000172:deficiency; D012016:Reference Values; D012310:Ristocetin / Q000494:pharmacology; D013915:Thrombasthenia / Q000097:blood / Q000175:diagnosis; D014842:von Willebrand Diseases / Q000097:blood / Q000175:diagnosis
D012310:Ristocetin; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D003094:Collagen; D011451:Prostaglandin-Endoperoxide Synthases